GlobalData on MSN13d
Lilly’s EBGLYSS shows improvement in Phase IIIb study for atopic dermatitis
The ADapt study assessed the efficacy and safety of EBGLYSS in individuals who had previously been treated with dupilumab.
Seeking Alpha16d
Lilly's Ebglyss shown to be effective in former Dupixent users
Eli Lilly (NYSE:LLY) said a Phase 3b study of its drug Ebglyss showed it was able to improve skin and itch in patients with moderate-to-severe atopic dermatitis who had previously been treated ...
Eli Lilly’s Ebglyss: A Promising Alternative for Dupixent-Resistant Atopic Dermatitis Patients
Leerink Partners analyst David Risinger has maintained their bullish stance on LLY stock, giving a Buy rating today. David Risinger’s ...
Eli Lilly's Ebglyss Emerges as New Option for Patients Struggling with Dupixent Treatment
Ebglyss proves effective in relieving dermatitis symptoms, showing promise as a substitute for Dupixent in challenging cases ...
Investing16d
Eli Lilly's EBGLYSS shows promise for eczema patients
INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY) announced that its drug EBGLYSS, an interleukin-13 (IL-13) inhibitor, has shown to improve skin condition and reduce itchiness in patients ...
Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent
Eli Lilly's Ebglyss improves skin and itch symptoms in eczema patients, including Dupixent-treated cases, with positive Phase ...
Nasdaq16d
Eli Lilly presents new Ebglyss data at FCD Conference
New results show Eli Lilly’s (LLY) Ebglyss improved skin and itch among patients with moderate-to-severe atopic dermatitis who were previously treated with dupilumab. These results from the ...
Investing16d
Eli Lilly's EBGLYSS shows promise for eczema patients
INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY) announced that its drug EBGLYSS, an interleukin-13 (IL-13) inhibitor, has shown to improve skin condition and reduce itchiness in patients with ...